Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2560 General Armistead Ave AUDUBON PA 19403-5214 |
Tel: | 1-610-9301800 |
Website: | https://www.globusmedical.com |
IR: | See website |
Key People | ||
David C. Paul Executive Chairman of the Board | Daniel T. Scavilla President, Chief Executive Officer, Director | Keith W. Pfeil Chief Financial Officer, Chief Operating Officer | Kelly Grace Huller Senior Vice President, General Counsel, Corporate Secretary |
Business Overview |
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip. |
Financial Overview |
For the fiscal year ended 31 December 2023, Globus Medical Inc revenues increased 53% to $1.57B. Net income decreased 35% to $122.9M. Revenues reflect Musculoskeletal Solutions products segment increase of 56% to $1.45B, Enabling Technologies products segment increase of 25% to $120.2M, United States segment increase of 47% to $1.28B, International segment increase of 91% to $288.7M. Net income was offset by Selling. |
Employees: | 5,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $7,162M as of Dec 31, 2023 |
Annual revenue (TTM): | $1,568M as of Dec 31, 2023 |
EBITDA (TTM): | $347.49M as of Dec 31, 2023 |
Net annual income (TTM): | $122.87M as of Dec 31, 2023 |
Free cash flow (TTM): | $165.23M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 136,335,662 as of Feb 16, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |